The European pancreatic cancer market is expected to grow modestly from USD 519 million in 2015, growing at a CAGR of 10-17%.
Globally, pancreatic cancer is the 12th most common cancer in men and 11th most common cancer in women. Addiction to cigarettes and health history are considered to be the foremost reasons increasing the risk.
Europe Pancreatic Cancer Therapeutics & Diagnostics Market-Market Dynamics
The report details several factors driving and restraining the market, some of which are listed below.
Some factors contributing to the growth of the market are:
Some factors limiting the growth of the market are:
The European pancreatic cancer therapeutics & diagnostic market is segmented based on the type of cancer into endocrine and exocrine cancers. By the type of treatment, the market is segmented into surgery, chemotherapy, radiation therapy and targeted therapy. By the major tests, the market has been segmented into biopsy, endoscopic ultrasound, laparoscopy and CT scan ERCP. On the basis of geography, the market has been segmented into Germany, France, Spain, Italy, the UK and Rest of Europe.
Some of the key players in the market are:
What the Report Offers
1.1 Market Definition
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Drivers
3.1.1 Large Number of Unmet Needs in the Disease
3.1.2 Increase in the Healthcare Expenditure
3.1.3 Increasing Concern across the Globe
3.2 Market Restraints
3.2.1 Inadequate Results after Treatment
3.2.2 Difficulties in Early Diagnosis
3.2.3 High Cost Associated with the Treatment
3.2.4 Low Success Rate in Clinical Trials for Cancer Drugs
3.3 Market Opportunities
3.4 Market Threats
4. Porter’s Five Force Analysis
4.1 Bargaining Power of Suppliers
4.2 Bargaining Power of Buyers
4.3 Degree of Competition
4.4 Threat of Substitution
4.5 Threat of New Entrants
5. Market Segmentation
5.1 Europe Pancreatic Cancer Therapeutics & Diagnostic Market, by Cancer Type
5.1.1 Exocrine Cancers
18.104.22.168 Pancreatic Adenocarcinoma
22.214.171.124 Acinar Cell Carcinoma
5.1.2 Endocrine Cancers (PanNETs)
5.2 Europe Pancreatic Cancer Therapeutics Market
5.2.3 Radiation Therapy
5.2.4 Chemoradiation Therapy
5.2.5 Targeted Therapy
5.3 Europe Pancreatic Cancer Diagnostics Market
5.3.2 Confirmatory Needle biopsy
5.3.3 Endoscopic Ultrasound
5.3.5 CT Scan
5.3.6 PET Scan
5.4 Europe Pancreatic Cancer Therapeutics Market, By Region
5.4.6 Rest of Europe
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations to New Market Players
7. Company Profiles
7.1 Amgen, Inc.
7.2 Eli Lilly and Company
7.3 Celgene Corporation
7.4 Clovis Oncology, Inc.
7.5 Novartis AG
7.6 Threshold Pharmaceuticals, Inc.
7.7 Incyte Corp
7.8 Merrimack Pharmaceuticals Inc.
7.9 Roche Ltd
7.10 NewLink Genetics